Denmark
# |
Name |
Revenue Per Share |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 37.34
|
Dec. 31, 2023 | USD 216.88 | 1.28% |
|
Denmark |
|
2 |
USD 17.94
|
Sept. 30, 2024 | USD 109.06 | -0.12% |
|
Denmark |
|
3 |
USD 13.63
|
Dec. 31, 2023 | USD 26.62 | -0.36% |
|
Denmark |
|
4 |
USD 9.56
|
Dec. 31, 2023 | USD 54.16 | -1.39% |
|
Denmark |
|
5 |
USD 7.67
|
Dec. 31, 2023 | USD 81.56 | -2.90% |
|
Denmark |
|
6 |
USD 5.23
|
Dec. 31, 2023 | USD 131.57 | -1.84% |
|
Denmark |
|
7 |
USD 3.37
|
June 30, 2024 | USD 70.50 | 0.61% |
|
Denmark |
|
8 |
USD 3.23
|
Dec. 31, 2023 | USD 20.15 | -0.78% |
|
Denmark |
|
9 |
USD 3.01
|
Sept. 30, 2024 | USD 18.73 | 1.26% |
|
Denmark |
|
10 |
USD 2.97
|
Dec. 31, 2023 | USD 5.46 | 0.56% |
|
Denmark |
|
11 |
USD 2.00
|
Dec. 31, 2023 | USD 91.43 | -1.85% |
|
Denmark |
|
12 |
USD 0.90
|
Dec. 31, 2023 | USD 95.84 | 0.08% |
|
Denmark |
|
13 |
USD 0.33
|
Dec. 31, 2023 | USD 0.85 | -3.38% |
|
Denmark |
|
14 |
USD 0.30
|
Dec. 31, 2023 | USD 1.93 | -6.19% |
|
Denmark |
|
15 |
USD 0.02
|
Dec. 31, 2023 | USD 0.57 | 1.47% |
|
Denmark |
|
16 |
USD 0.02
|
Dec. 31, 2023 | USD 2.17 | 5.88% |
|
Denmark |
|
17 |
USD 0.01
|
Dec. 31, 2023 | USD 0.20 | -2.77% |
|
Denmark |
|
18 |
USD 0.01
|
Dec. 31, 2023 | USD 3.98 | 0.01% |
|
Denmark |
|
19 |
USD 0.00
|
Dec. 31, 2023 | USD 0.64 | 1.38% |
|
Denmark |
The Pharmaceuticals company in Denmark with the highest Revenue Per Share is Genmab A/S (Copenhagen Stock Exchange: GMAB.CO) at USD 37.34.
The Pharmaceuticals company in Denmark with the lowest Revenue Per Share is Initiator Pharma A/S (Stockholm Stock Exchange: INIT.ST) at USD 0.00.
The top 10 Pharmaceuticals companies in Denmark by Revenue Per Share are Genmab A/S, Coloplast A/S, Bavarian Nordic A/S, Novozymes A/S, Novo Nordisk A/S, Ascendis Pharma A/S, ChemoMetec A/S, ALK-Abelló A/S, Ambu A/S and H. Lundbeck A/S.
The bottom 10 Pharmaceuticals companies in Denmark by Revenue Per Share are Initiator Pharma A/S, FluoGuide A/S, BioPorto A/S, ExpreS2ion Biotech Holding AB (publ), Saniona AB (publ), ViroGates A/S, Q-Interline A/S, Zealand Pharma A/S, Gubra A/S and H. Lundbeck A/S.